The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma

E Franceschi, N Drick, J Fuge, P Santus… - ERJ Open …, 2023 - Eur Respiratory Soc
Introduction Exercise limitation is frequently described among asthmatic patients and could
be related to different mechanisms of the pulmonary, cardiovascular and muscular systems …

[HTML][HTML] Omalizumab treatment and exercise capacity in severe asthmatics–results from a pilot study

C Schäper, S Gläser, SB Felix, A Gogolka, B Koch… - Respiratory …, 2011 - Elsevier
BACKGROUND: In patients with moderate to severe allergic asthma, clinical effectiveness of
omalizumab, an approved anti-IgE-reacting substance, is usually assessed by pulmonary …

Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody

L Antonicelli, A Gobbi, MB Bilo, MS Garritani… - 2018 - Eur Respiratory Soc
Background: Steroid-dependent or severe eosinophilic asthma prone to exacerbations
despite maximal ICS/LABA dose are a potential candidate for Mepolizumab. While …

Late Breaking Abstract-Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy

M Panagiotou, N Koulouris, A Koutsoukou, M Tsami… - 2019 - Eur Respiratory Soc
Background: Daily physical activity (DLA) in patients with severe asthma remains
inadequately explored. The potential effect of biological therapy in DLA in patients with …

Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma

C Lombardi, A Berti, M Cottini, E Roca… - ERJ Open …, 2023 - Eur Respiratory Soc
Background Severe asthma limits exercise to avoid respiratory symptoms. The objective of
the present study was to investigate the role of the 6-min walk test (6MWT) in severe asthma …

[HTML][HTML] Mepolizumab improves small airway function in severe eosinophilic asthma

CS Farah, T Badal, N Reed, PG Rogers, GG King… - Respiratory …, 2019 - Elsevier
Background and objective Treatment with mepolizumab in severe eosinophilic asthma
(SEA) significantly reduces exacerbations with modest improvements in symptom control …

Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study

DD Pham, JH Lee, HS Kwon, WJ Song, YS Cho, H Kim… - Lung, 2024 - Springer
Background The determinants linked to the short-and long-term improvement in lung
function in patients with severe eosinophilic asthma (SEA) on biological treatment (BioT) …

[HTML][HTML] Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma

A Maglio, C Vitale, S Pellegrino, C Calabrese… - Biomedicines, 2021 - mdpi.com
Severe eosinophilic asthma (SEA) is associated with high peripheral blood and airway
eosinophilia, recurrent disease exacerbations and severe airflow limitation. Eosinophilic …

Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy

A Maglio, C Vitale, S Pellegrino, C Calabrese… - 2020 - Eur Respiratory Soc
Background: Asthma is a disease characterized by heterogeneity in clinical presentation
and pathophysiological mechanisms. A novel element of new studies is the role of the …

Late Breaking Abstract-The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma

M Przybyszowski, I Gross-Sondej, J Zarychta… - 2021 - Eur Respiratory Soc
Background: Severe eosinophilic asthma involves chronic inflammatory process in the
airways leading to changes in airway structure, known as airway remodeling. IL-5 is a …